Schedule 13D ownership disclosure

ITEOS THERAPEUTICS INC

Common Stock · CUSIP: 46565G104

Event date: 2025-05-13

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • MPM BioVentures 2014, L.P.Reported CIK 0001609492

    Shares: 621,312.00 · Class: 1.6%

  • MPM BioVentures 2014 (B), L.P.Reported CIK 0001609493

    Shares: 39,135.00 · Class: 0.1%

  • MPM Asset Management Investors BV2014 LLCReported CIK 0001609495

    Shares: 21,385.00 · Class: 0.1%

  • MPM BIOVENTURES 2018, L.P.Reported CIK 0001729505

    Shares: 392,407.00 · Class: 1.0%

  • MPM BIOVENTURES 2018 (B), L.P.Reported CIK 0001729504

    Shares: 19,697.00 · Class: 0.1%

  • MPM ASSET MANAGEMENT INVESTORS BV2018 LLCReported CIK 0001734817

    Shares: 7,749.00 · Class: 0.0%

  • UBS Oncology Impact Fund L.P.Reported CIK 0001691428

    Shares: 702,311.00 · Class: 1.8%

  • MPM BioVentures 2014 GP LLCReported CIK 0001765091

    Shares: 660,447.00 · Class: 1.7%

  • MPM BioVentures 2014 LLCReported CIK 0001765021

    Shares: 681,832.00 · Class: 1.8%

  • MPM BioVentures 2018 GP LLCReported CIK 0001818701

    Shares: 412,104.00 · Class: 1.1%

  • MPM BioVentures 2018 LLCReported CIK 0001818702

    Shares: 419,853.00 · Class: 1.1%

  • Oncology Impact Fund (Cayman) Management L.P.Reported CIK 0001721036

    Shares: 702,311.00 · Class: 1.8%

  • MPM BioImpact LLCReported CIK 0001687078

    Shares: 702,311.00 · Class: 1.8%

  • ANSBERT GADICKEReported CIK 0001134655

    Shares: 1,803,996.00 · Class: 4.7%

  • LUKE EVNINReported CIK 0001134657

    Shares: 1,101,685.00 · Class: 2.9%

  • Todd FoleyReported CIK 0001473930

    Shares: 1,101,685.00 · Class: 2.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001415889-25-013244
Form type
SCHEDULE 13D/A
Filer
MPM BioVentures 2014, L.P.
CIK
CIK 1609492
Filed
May 15, 2025
Reporting period
May 13, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub